

Short Bowel Syndrome Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region, By Competition

<https://marketpublishers.com/r/SDF48237958EEN.html>

Date: November 2023

Pages: 190

Price: US\$ 4,900.00 (Single User License)

ID: SDF48237958EEN

Abstracts

Global Short Bowel Syndrome Market has valued at USD 805.11 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.24% through 2028. Short Bowel Syndrome (SBS) is a rare but debilitating medical condition that affects the digestive system, particularly the small intestine. Individuals with SBS have a reduced ability to absorb nutrients and fluids, leading to malnutrition, dehydration, and a host of other health complications. The global Short Bowel Syndrome market has witnessed significant advancements in recent years, offering hope to patients and healthcare providers alike.

Short Bowel Syndrome is primarily a result of surgical removal or damage to a significant portion of the small intestine. This can occur due to various factors, such as congenital defects, trauma, or diseases like Crohn's disease. The condition manifests through symptoms like diarrhea, malabsorption of nutrients, electrolyte imbalances, and weight loss. The global Short Bowel Syndrome market has experienced substantial growth in recent years. Several factors contribute to this, including an increased awareness of the condition, advances in medical technology, and a growing patient population. The prevalence of Short Bowel Syndrome has been on the rise, driving the demand for effective treatment options. This increase can be attributed to better diagnostic techniques and an aging population. Traditional treatment approaches for SBS focused on dietary management and parenteral nutrition. However, the market has

seen a shift towards innovative therapies such as intestinal rehabilitation, microbiome-based treatments, and tissue engineering. Several pharmaceutical companies and research institutions are actively involved in the development of therapies and drugs for SBS. These players compete in a dynamic market, fostering innovation and new discoveries.

Ky Market Drivers

Increasing Incidence of Short Bowel Syndrome is Driving the Global Short Bowel Syndrome Market

The rise in Short Bowel Syndrome cases has led to an increased demand for treatments and therapies, which in turn is driving the growth of the global Short Bowel Syndrome market. The pharmaceutical industry has been investing in research and development to create medications that can help patients with SBS better absorb nutrients and manage their condition. These innovations are contributing to the growth of the market. Patients with SBS often require parenteral nutrition, which involves receiving essential nutrients intravenously. The demand for parenteral nutrition solutions and associated equipment has surged, leading to market expansion. In addition to parenteral nutrition, enteral nutrition plays a vital role in managing SBS. The market for specialized enteral formulas tailored to SBS patients is also growing. Minimally invasive surgical techniques and small bowel transplantation have improved outcomes for SBS patients. These advancements are contributing to the market's expansion. Increased awareness of Short Bowel Syndrome and the advocacy efforts of patient groups have led to more resources and research funding being allocated to the disease, further stimulating market growth.

The increasing incidence of Short Bowel Syndrome is a pressing healthcare concern that is driving the growth of the global Short Bowel Syndrome market. Factors such as medical advancements, improved survival rates for preterm infants, and the rising prevalence of inflammatory bowel diseases are contributing to this trend. The pharmaceutical, nutritional, and surgical sectors are all responding with innovations and treatments to improve the lives of those affected by SBS. As research and development continue to advance, there is hope for better management and improved outcomes for individuals living with this challenging condition.

Rising Investment in Research and Development is Driving the Global Short Bowel Syndrome Market

The global Short Bowel Syndrome market is experiencing a significant boost due to increased investment in R&D activities. This surge in funding is primarily driven by a growing understanding of the disease, advancements in medical technology, and a commitment to improving the quality of life for SBS patients.

Recent R&D initiatives have led to the development of innovative therapies that address the underlying causes of SBS. One such breakthrough is the development of tissue-engineered intestines, which have the potential to replace damaged or missing parts of the small intestine. These therapies hold promise for SBS patients who previously had limited treatment options. R&D efforts have also resulted in the creation of specialized nutritional formulations tailored to the unique needs of SBS patients. These formulations help patients meet their nutritional requirements and improve their overall health and well-being. This has led to an increased demand for such products in the market. Pharmaceutical companies are actively investing in the development of drugs that can enhance nutrient absorption in SBS patients. These drugs aim to reduce dependence on parenteral nutrition (intravenous feeding) and improve patients' ability to absorb nutrients orally, ultimately improving their quality of life. The surge in R&D investment has led to a rise in clinical trials focused on Short Bowel Syndrome. These trials not only help in evaluating the safety and efficacy of new treatments but also provide valuable data that can guide further research and development efforts.

The rising investment in research and development is transforming the landscape of the global Short Bowel Syndrome market. With innovative therapies, advanced nutritional support, and promising drug candidates in the pipeline, SBS patients can look forward to improved treatment options and a better quality of life. As R&D efforts continue to flourish, it is likely that the market will expand further, offering hope to those affected by this rare and challenging condition. Ultimately, the synergy between research, investment, and patient advocacy is driving the global Short Bowel Syndrome market toward a brighter future.

Key Market Challenges

Limited Patient Pool

One of the primary challenges faced by the Global Short Bowel Syndrome Market is the limited patient pool. SBS is considered a rare disease, with only a relatively small number of diagnosed cases worldwide. This limited patient base makes it economically challenging for pharmaceutical companies to invest in the development of specialized treatments and therapies for SBS. Consequently, potential breakthroughs may not

receive the funding and attention they deserve.

High Treatment Costs

The treatment of SBS is notoriously expensive. Patients often require lifelong medical care, including parenteral nutrition and specialized medications. Additionally, the cost of surgery and post-operative care can be substantial. As a result, patients, healthcare systems, and insurance providers face the daunting challenge of covering these high treatment costs, potentially leading to financial strain and limited access to care.

Nutritional Challenges

Patients with SBS often struggle to maintain proper nutrition and fluid balance due to the reduced length of their small intestine. Nutritional deficiencies and dehydration are common issues, necessitating ongoing dietary management and the use of specialized nutritional supplements. Ensuring that patients receive adequate nutrition while minimizing complications is a complex and ongoing challenge.

Development of Effective Therapies

The development of effective therapies for SBS is an ongoing struggle. While there have been some advances in the form of medications and medical devices, there is no one-size-fits-all treatment for this condition. Researchers face the challenge of tailoring therapies to individual patients, considering factors such as the length of the remaining intestine and the underlying cause of SBS. This level of customization makes treatment development complex and resource-intensive.

Lack of Awareness and Diagnosis

SBS is often misdiagnosed or diagnosed at a late stage, primarily because of its rarity and the absence of specific symptoms. This delay in diagnosis can lead to complications and worsen the patient's condition. Raising awareness among healthcare professionals and the general public about the symptoms and risk factors associated with SBS is crucial for early intervention and improved outcomes.

Regulatory and Market Access Barriers

Navigating the regulatory landscape for SBS treatments can be challenging. The approval process for new therapies can be lengthy and complex, and ensuring market

access for these treatments can be a significant hurdle. Companies must demonstrate the safety and efficacy of their products while addressing the unique needs of the SBS patient population.

Quality of Life and Long-Term Outcomes

Beyond medical treatment, patients with SBS face ongoing challenges related to their quality of life and long-term outcomes. Managing SBS often involves adapting to dietary restrictions, dealing with complications such as intestinal failure-associated liver disease, and coping with the emotional and psychological impact of the condition. Addressing these aspects of SBS care is essential for comprehensive patient management.

Key Market Trends

Technological Advancements

Short Bowel Syndrome (SBS) is a rare, yet debilitating condition that affects individuals who have lost a significant portion of their small intestine, typically due to surgery or disease. This condition can lead to severe malabsorption of nutrients, causing patients to suffer from malnutrition and other related complications. Fortunately, recent advancements in medical technology have been driving significant growth in the global Short Bowel Syndrome market, offering hope to those afflicted with this condition. The global Short Bowel Syndrome market has been witnessing substantial growth in recent years. Several factors are contributing to this expansion, with technological advancements playing a pivotal role. Pharmaceutical companies have been actively developing new drugs and therapies to address the underlying causes and symptoms of SBS. These innovations aim to enhance nutrient absorption and improve the quality of life for SBS patients. Advances in the development of specialized nutritional supplements tailored to the unique needs of SBS patients have improved the management of this condition. These supplements help individuals maintain a balanced diet and prevent malnutrition. Technological advancements in surgical techniques have made it possible to reconstruct the remaining intestine more effectively, allowing for better nutrient absorption. Minimally invasive surgical procedures reduce complications and recovery times. The rise of telemedicine has made it easier for SBS patients to access healthcare professionals and receive ongoing care. Remote monitoring and teleconsultations enable better disease management and early intervention. Mobile applications and wearable devices have emerged to help patients track their nutrition, manage symptoms, and communicate with their healthcare providers more effectively.

These tools empower patients to take control of their health and engage in self-care. Ongoing research in gene therapy holds promise for potential long-term solutions to SBS. By modifying genes responsible for nutrient absorption, scientists aim to develop therapies that can restore intestinal function.

The global Short Bowel Syndrome market is undergoing a transformation driven by remarkable technological advancements. These innovations are improving the lives of SBS patients by offering more effective treatments, better nutritional support, and enhanced monitoring options. As pharmaceutical companies continue to invest in research and development, and medical technology continues to evolve, there is optimism that the future holds even more promising solutions for individuals suffering from Short Bowel Syndrome. This progress not only provides hope for those afflicted with the condition but also underscores the broader potential of technology to revolutionize healthcare across various medical domains.

Drug Class Insights

The Glutamine segment is projected to experience rapid growth during the forecast period. Glutamine is an amino acid naturally present in the body, with a vital role in various metabolic processes. In recent years, it has gained prominence in the treatment of Short Bowel Syndrome, owing to its ability to support intestinal health and improve nutrient absorption. Glutamine is available in both oral and intravenous forms, making it a versatile choice for SBS patients. Clinical studies have shown that Glutamine supplementation can help maintain the integrity of the intestinal mucosa, reduce diarrhea, and improve nutrient absorption. This translates to better nutritional outcomes for SBS patients. Glutamine is generally well-tolerated and has a favorable safety profile. This makes it a preferred choice for long-term use, reducing the risk of adverse effects commonly associated with other treatments like PN. The availability of both oral and intravenous forms of Glutamine allows healthcare providers to tailor treatment to individual patient needs. This flexibility is crucial for optimizing therapy.

Distribution Channel Insights

The Hospital Pharmacies segment is projected to experience rapid growth during the forecast period. Hospital pharmacies work closely with healthcare professionals to create customized medications and intravenous (IV) solutions for SBS patients. These medications are tailored to meet each patient's specific nutritional needs, helping to mitigate the symptoms and complications of the condition. SBS patients often require specialized nutrition support, such as Total Parenteral Nutrition (TPN) or Enteral

Nutrition (EN). Hospital pharmacies are equipped to compound these nutritional formulas, ensuring that patients receive the appropriate nutrients and fluids to maintain their health. Hospital pharmacies have the infrastructure and expertise to stock and dispense specialized medications and therapies designed to treat SBS, such as teduglutide (Gattex) and loperamide. They ensure that patients have access to these crucial treatments without delays.

Regional Insights

North America emerged as the dominant player in the global Short Bowel Syndrome market in 2022, holding the largest market share in terms of value. North America has long been at the forefront of medical research and development, and this holds true for SBS as well. The region boasts a robust infrastructure of research institutions, pharmaceutical companies, and healthcare facilities. Prominent universities and medical centers in the United States and Canada have actively engaged in clinical trials and research initiatives aimed at improving SBS management. The United States Food and Drug Administration (FDA) and Health Canada are renowned for their stringent yet efficient regulatory processes. These agencies play a pivotal role in ensuring the safety and efficacy of new SBS treatments. Companies operating in North America benefit from a transparent and well-defined regulatory pathway, which encourages innovation and investment in the SBS market. North America is home to some of the world's largest pharmaceutical companies, many of which have invested heavily in SBS research and development. These industry giants have the financial capacity and expertise to conduct extensive clinical trials and bring innovative treatments to market. Their involvement in the SBS market has driven significant advancements in treatment options.

Key Market Players

9 Meters Biopharma, Inc.

Wellspect Healthcare

Emmaus Life Sciences, Inc.

Merck KGaA

Nestle S.A.

Novartis International AG

OPKO Health, Inc.

Oxthera AB

Pfizer Inc.

PhaseBio Pharmaceuticals Inc.

Sancilio and Company, Inc.

Swedish Orphan Biovitrum AB

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Short Bowel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short Bowel Syndrome Market, By Drug Class:

GLP-2

Glutamine

Growth Hormone

Short Bowel Syndrome Market, By Distribution Channel:

Hospital Pharmacies

Online Sales

Retail Pharmacies

Short Bowel Syndrome Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Short Bowel Syndrome Market.

Available Customizations:

Global Short Bowel Syndrome market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL SHORT BOWEL SYNDROME MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Drug Class (GLP-2, Glutamine, and Growth Hormone)
 - 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies)
 - 5.2.3. By Region

- 5.2.4. By Company (Shares of Top 5 Market Players)
- 5.3. Market Map
 - 5.3.1. By Drug Class
 - 5.3.2. By Distribution Channel
 - 5.3.3. By Region

6. NORTH AMERICA SHORT BOWEL SYNDROME MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Drug Class
 - 6.2.2. By Distribution Channel
 - 6.2.3. By Country
 - 6.2.3.1. United States Short Bowel Syndrome Market Outlook
 - 6.2.3.1.1. Market Size & Forecast
 - 6.2.3.1.1.1. By Value
 - 6.2.3.1.2. Market Share & Forecast
 - 6.2.3.1.2.1. By Drug Class
 - 6.2.3.1.2.2. By Distribution Channel
 - 6.2.3.2. Canada Short Bowel Syndrome Market Outlook
 - 6.2.3.2.1. Market Size & Forecast
 - 6.2.3.2.1.1. By Value
 - 6.2.3.2.2. Market Share & Forecast
 - 6.2.3.2.2.1. By Drug Class
 - 6.2.3.2.2.2. By Distribution Channel
 - 6.2.3.3. Mexico Short Bowel Syndrome Market Outlook
 - 6.2.3.3.1. Market Size & Forecast
 - 6.2.3.3.1.1. By Value
 - 6.2.3.3.2. Market Share & Forecast
 - 6.2.3.3.2.1. By Drug Class
 - 6.2.3.3.2.2. By Distribution Channel

7. EUROPE SHORT BOWEL SYNDROME MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Drug Class

7.2.2. By Distribution Channel

7.2.3. By Country

7.2.3.1. France Short Bowel Syndrome Market Outlook

7.2.3.1.1. Market Size & Forecast

7.2.3.1.1.1. By Value

7.2.3.1.2. Market Share & Forecast

7.2.3.1.2.1. By Drug Class

7.2.3.1.2.2. By Distribution Channel

7.2.3.2. Germany Short Bowel Syndrome Market Outlook

7.2.3.2.1. Market Size & Forecast

7.2.3.2.1.1. By Value

7.2.3.2.2. Market Share & Forecast

7.2.3.2.2.1. By Drug Class

7.2.3.2.2.2. By Distribution Channel

7.2.3.3. United Kingdom Short Bowel Syndrome Market Outlook

7.2.3.3.1. Market Size & Forecast

7.2.3.3.1.1. By Value

7.2.3.3.2. Market Share & Forecast

7.2.3.3.2.1. By Drug Class

7.2.3.3.2.2. By Distribution Channel

7.2.3.4. Italy Short Bowel Syndrome Market Outlook

7.2.3.4.1. Market Size & Forecast

7.2.3.4.1.1. By Value

7.2.3.4.2. Market Share & Forecast

7.2.3.4.2.1. By Drug Class

7.2.3.4.2.2. By Distribution Channel

7.2.3.5. Spain Short Bowel Syndrome Market Outlook

7.2.3.5.1. Market Size & Forecast

7.2.3.5.1.1. By Value

7.2.3.5.2. Market Share & Forecast

7.2.3.5.2.1. By Drug Class

7.2.3.5.2.2. By Distribution Channel

8. ASIA PACIFIC SHORT BOWEL SYNDROME MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

- 8.2.2. By Distribution Channel
- 8.2.3. By Country
 - 8.2.3.1. China Short Bowel Syndrome Market Outlook
 - 8.2.3.1.1. Market Size & Forecast
 - 8.2.3.1.1.1. By Value
 - 8.2.3.1.2. Market Share & Forecast
 - 8.2.3.1.2.1. By Drug Class
 - 8.2.3.1.2.2. By Distribution Channel
 - 8.2.3.2. India Short Bowel Syndrome Market Outlook
 - 8.2.3.2.1. Market Size & Forecast
 - 8.2.3.2.1.1. By Value
 - 8.2.3.2.2. Market Share & Forecast
 - 8.2.3.2.2.1. By Drug Class
 - 8.2.3.2.2.2. By Distribution Channel
 - 8.2.3.3. South Korea Short Bowel Syndrome Market Outlook
 - 8.2.3.3.1. Market Size & Forecast
 - 8.2.3.3.1.1. By Value
 - 8.2.3.3.2. Market Share & Forecast
 - 8.2.3.3.2.1. By Drug Class
 - 8.2.3.3.2.2. By Distribution Channel
 - 8.2.3.4. Japan Short Bowel Syndrome Market Outlook
 - 8.2.3.4.1. Market Size & Forecast
 - 8.2.3.4.1.1. By Value
 - 8.2.3.4.2. Market Share & Forecast
 - 8.2.3.4.2.1. By Drug Class
 - 8.2.3.4.2.2. By Distribution Channel
 - 8.2.3.5. Australia Short Bowel Syndrome Market Outlook
 - 8.2.3.5.1. Market Size & Forecast
 - 8.2.3.5.1.1. By Value
 - 8.2.3.5.2. Market Share & Forecast
 - 8.2.3.5.2.1. By Drug Class
 - 8.2.3.5.2.2. By Distribution Channel

9. SOUTH AMERICA SHORT BOWEL SYNDROME MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Drug Class

- 9.2.2. By Distribution Channel
- 9.2.3. By Country
 - 9.2.3.1. Brazil Short Bowel Syndrome Market Outlook
 - 9.2.3.1.1. Market Size & Forecast
 - 9.2.3.1.1.1. By Value
 - 9.2.3.1.2. Market Share & Forecast
 - 9.2.3.1.2.1. By Drug Class
 - 9.2.3.1.2.2. By Distribution Channel
 - 9.2.3.2. Argentina Short Bowel Syndrome Market Outlook
 - 9.2.3.2.1. Market Size & Forecast
 - 9.2.3.2.1.1. By Value
 - 9.2.3.2.2. Market Share & Forecast
 - 9.2.3.2.2.1. By Drug Class
 - 9.2.3.2.2.2. By Distribution Channel
 - 9.2.3.3. Colombia Short Bowel Syndrome Market Outlook
 - 9.2.3.3.1. Market Size & Forecast
 - 9.2.3.3.1.1. By Value
 - 9.2.3.3.2. Market Share & Forecast
 - 9.2.3.3.2.1. By Drug Class
 - 9.2.3.3.2.2. By Distribution Channel

10. MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Drug Class
 - 10.2.2. By Distribution Channel
 - 10.2.3. By Country
 - 10.2.3.1. South Africa Short Bowel Syndrome Market Outlook
 - 10.2.3.1.1. Market Size & Forecast
 - 10.2.3.1.1.1. By Value
 - 10.2.3.1.2. Market Share & Forecast
 - 10.2.3.1.2.1. By Drug Class
 - 10.2.3.1.2.2. By Distribution Channel
 - 10.2.3.2. Saudi Arabia Short Bowel Syndrome Market Outlook
 - 10.2.3.2.1. Market Size & Forecast
 - 10.2.3.2.1.1. By Value
 - 10.2.3.2.2. Market Share & Forecast

- 10.2.3.2.2.1. By Drug Class
- 10.2.3.2.2.2. By Distribution Channel
- 10.2.3.3. UAE Short Bowel Syndrome Market Outlook
 - 10.2.3.3.1. Market Size & Forecast
 - 10.2.3.3.1.1. By Value
 - 10.2.3.3.2. Market Share & Forecast
 - 10.2.3.3.2.1. By Drug Class
 - 10.2.3.3.2.2. By Distribution Channel

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Technology Launches

13. COMPETITIVE LANDSCAPE

- 13.1. 9 Meters Biopharma, Inc.
 - 13.1.1. Business Overview
 - 13.1.2. Patient Offerings
 - 13.1.3. Recent Developments
 - 13.1.4. Key Personnel
 - 13.1.5. SWOT Analysis
- 13.2. Wellspect Healthcare
- 13.3. Emmaus Life Sciences, Inc.
- 13.4. Merck KGaA
- 13.5. Nestle S.A.
- 13.6. Novartis International AG
- 13.7. OPKO Health, Inc.
- 13.8. Oxthera AB
- 13.9. Pfizer Inc.
- 13.10. PhaseBio Pharmaceuticals Inc.
- 13.11. Sancilio and Company, Inc.
- 13.12. Swedish Orphan Biovitrum AB

13.13. Takeda Pharmaceutical Company Limited

13.14. Teva Pharmaceutical Industries Ltd.

14. STRATEGIC RECOMMENDATIONS

About us & Disclaimer

I would like to order

Product name: Short Bowel Syndrome Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region, By Competition

Product link: <https://marketpublishers.com/r/SDF48237958EEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SDF48237958EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970